Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sentinel Oncology, Oncothyreon Collaborate on Small Molecule Chk1 Inhibitors

Published: Tuesday, April 22, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
The Agreement is for the development of Sentinel’s Checkpoint Kinase 1 (Chk1) programme.

Sentinel Oncology Ltd. today announced it has signed a collaboration agreement with Oncothyreon Inc. for development of Sentinel’s Checkpoint Kinase 1 (Chk1) programme. Under the terms of the agreement Oncothyreon will fund additional drug discovery research at Sentinel directed at the Chk1 target, and will have an exclusive license for the development and commercialisation of any resulting compounds. Sentinel is eligible to receive pre-clinical, clinical and commercial milestone payments of up to $174M and a royalty on net sales, if any.

Sentinel has developed a series of potent, selective, orally active Chk1 kinase inhibitors as chemo- and radio-sensitizers. Chemotherapy and radiotherapy are among the most commonly used cancer treatments and work by damaging the DNA of tumour cells. The Chk1 protein performs a crucial role in the way that cancer cells respond to DNA damage and although Chk1 is active in all cells, over 50% of tumour cells have partially disrupted DNA repair mechanisms and are therefore much more reliant on Chk1. Consequently, inhibition of Chk1 has been shown to selectively sensitise tumour cells to DNA damaging agents, enabling effective lower doses of chemo- and radiotherapy, and reduction in associated side-effects.

Robert L. Kirkman, M.D., President and CEO, Oncothyreon, said: “We are pleased to add to our oncology pipeline through this collaboration with Sentinel. Selective inhibitors of Chk1 have implications across a broad range of cancer types and we believe this programme has the potential to make a positive impact on the lives of many cancer patients.”

Bob Boyle, CEO, Sentinel, commented: “We are delighted that Oncothyreon has recognised the value of our Chk1 programme. It is an exciting target, and we look forward to capitalising on Oncothyreon’s expertise in order to drive the programme forward into clinical studies.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos